Cannabis Science, Inc. (CBIS) Releases Clinical Drug-Development Pipeline

Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, hits inflection point that translates into an unprecedented progression to clinical trials. With this change of atmosphere, the company is proud to release its 2019 Clinical Drug Development Pipeline and categorized industry sector inventory lists. Significant success targeting several high-profile critical ailments with clinical drug development translations and more announcements at the upcoming Global Health Catalyst (GHC) Summit at Harvard Medical School. The Summit is scheduled for May 24-26, 2019 in Boston, MA.

Cannabis Science has invested significantly in its pre-clinical research programs and has observed promising results for the use of cannabinoids to treat a number of targeted indications through its multiple State by State product releases and over the counter market test product releases. The Company and its collaborators have investigated varying doses of cannabinoids, and rigorously evaluated treatment outcomes, efficacy, and toxicity to generate data that will translate into clinical trials. “While our research program continues, we believe we have products that are ready for clinical trials this year,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder. “We are currently forming our clinical-trials team, to include our Principal Investigators and other relevant personnel in Canada and the United States.”

Please click the chart on the front page of the Company website; www.cannabisscience.com

The Company produces cannabinoid-based product lines for three industry sectors:

1.     Federal Regulatory, prescription based;

2.     State Regulatory, state by state;

3.     Over-the-counter, non-prescription.

CBIS and its research collaborators are currently conducting pre-clinical research on cannabinoid-based medicines to treat Lung Cancer, Pancreatic Cancer, Chronic Prostatitis, Obsessive Compulsive Disorder (OCD), Oro-bucco-lingual Dyskinesias, Oxidative Stress, Psychosis, and Post Traumatic Stress Disorder (PTSD), and other indications.

“Of the clinical prescription drugs that we are developing right now, we believe the first ones to be ready for clinical trials will be those with the potential to treat various cancers,” added Mr. Dabney.

CBIS and its collaborators have published two peer-reviewed research papers in the cancer research journal, Frontiers in Oncology; both articles rose to the top 98% impact rating of all Frontiers Articles:

Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids:

https://www.frontiersin.org/articles/10.3389/fonc.2017.00208/full

Enhancing the Therapeutic Efficacy of Cancer Treatment with Cannabinoids:

https://www.frontiersin.org/articles/10.3389/fonc.2018.00114/full

“This is truly an exciting time for CBIS. With our research collaborators, we have potential products under development that could help millions of people worldwide. The question now becomes how many of our clinical translations could ultimately become a blockbuster drug? At this stage, we have to continue to aggressively invest in our research and hopefully prove the effectiveness of our products via clinical trials. Step-by-step, we continue to move forward,” concludes Mr. Dabney.

The Harvard GHC Summit is a premier, annual event dedicated to catalyzing high-impact international collaborations to eliminate global health disparities, with the main focus on cancer and related diseases. Since 2015, the yearly summits are part of a series of high impact initiatives of the Harvard Global Health Catalyst (http://ghc.bwh.harvard.edu/) funded by the Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Radcliffe Institute for Advanced Studies at Harvard University, and a growing number of international institution partners.

For more information on the 2019 GHC Summit at Harvard Medical School, please visit:

https://www.globalhealthcatalystsummit.org/

About Cannabis Science, Inc. 

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.